Targeting a Novel Phosphoinositide Signaling Pathway for Cancer Therapy

癌症治疗的巨大进步将取决于为治疗寻找新的靶点。在这里，我们提出了一个我们发现的新的肌醇磷脂信号通路作为候选靶点。我们已经确定了一条涉及磷脂酰肌醇PtdIns(4)P的途径和一种与其结合的新蛋白，该蛋白 我们称之为PI4P-BP。我们已经证明，这条途径是正常高尔基体结构和功能所必需的。癌细胞通常需要自分泌、旁分泌或内分泌生长因子信号才能持续增殖和存活。由于生长因子和生长因子受体的运输需要完整的高尔基体功能，干扰高尔基体有望干扰癌症的增殖和生存。我们设计了诱导干扰PtdIns(4)P/PI4P-BP通路的方法。我们建议进行实验，以确定干扰PtdIns(4)P/PI4P-BP通路对生长因子信号的影响，从而确定是否值得进一步开发这一新的治疗策略以应用于临床。

Dramatic advances in cancer treatment will depend on identifying new targets for therapeutics. Here we propose as a candidate target a novel phosphoinositide signaling pathway that we have discovered. We have identified a pathway involving the phosphoinositide PtdIns(4)P and a new protein that binds to it which we have called PI4P-BP. We have shown that this pathway is required for normal Golgi architecture and function. Cancer cells often require autocrine, paracrine, or endocrine growth factor signaling for continued proliferation and survival. Since trafficking of growth factors and growth factor receptors requires intact Golgi function, interference with the Golgi is expected to interfere with cancer proliferation and survival. We have devised methods to inducibly interfere with the PtdIns(4)P/PI4P-BP pathway. We propose experiments to determine the effect of interference with the PtdIns(4)P/PI4P-BP pathway on growth factor signaling and thus whether it will be worthwhile to develop this novel therapeutic strategy further toward its clinical application.